

For Immediate Release

Q2 Net Profit at Rs 119 cr, Net Revenues at Rs 879 cr

Vadodara October 25th, 2016

Alembic Pharmaceuticals Limited reported its consolidated financial results for the second quarter ending 30th September 2016.

Financial Highlights

- Net Sales for Q2 FY 2016-17 were at Rs 879 crores as against Rs 1017 crores during the same period in last year
- Net Profit for Q2 FY 2016-17 were at Rs 119 crores as against Rs 288 crores during the same period in last year
- Previous period includes revenues and profits from a Para IV new product launch in the US market, which had limited competition last year.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said "Our base business in the US market is doing well. We will continue to invest in R&D for the future growth and have spent Rs 115 cr in the quarter on R&D, which is up from Rs 78 crores."

Operational Highlights for the quarter

International Business

- International formulation business at Rs. 352 crores for Q2 FY 2016-17 as against Rs 571 crores during the same period in last year
- 2 ANDA tentative approvals were received, Cumulative ANDA approvals at 49
- 4 ANDA applications were filed, Cumulative ANDA filings at 82

India Branded Formulations

- India Branded formulations grew 19% to Rs. 338 crore
- Acute segment grew by 22% and Specialty segment grew 16%
 - o Cough & Cold 35%
 - o Gynaecology up 34%
 - o Anti Diabetic up 28%



Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q2 FY17	Q2 FY16	H1 FY17	H1 FY16				
Formulation				-				
International	352	571	660	750				
India Branded India Generics API Total	338 25 164	284 25 137	616 46 293	546 54 257				
					879	1017	1615	1607

The Profit break-up is as under:

(Rs in Crores)

Particulars	Q2 FY17	Q2 FY16	H1 FY17	H1 FY16
EBITDA	178	376	335	480
Profit Before Tax	157	362	294	453
Net Profit after Tax	119	288	221	358

CIN: L24230GJ2010PLC061123



About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai Mitanshu Shah

Phone: +91 22 - 306 11681 Phone: +91 265 - 3007630

Email: ajay.desai@alembic.co.in | Email: mitanshu.shah@alembic.co.in

CIN: L24230GJ2010PLC061123